Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

3MVJ

Human cyclic AMP-dependent protein kinase PKA inhibitor complex

Summary for 3MVJ
Entry DOI10.2210/pdb3mvj/pdb
Related3MV5 3MVH
DescriptorcAMP-dependent protein kinase catalytic subunit alpha, cAMP-dependent protein kinase inhibitor alpha, (3R)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-3-amine, ... (4 entities in total)
Functional Keywordskinase inhibitor, transferase
Biological sourceHomo sapiens (human)
Cellular locationCytoplasm. Isoform 2: Cell projection, cilium, flagellum : P17612
Total number of polymer chains6
Total formula weight136053.52
Authors
Pandit, J.,Vajdos, F. (deposition date: 2010-05-04, release date: 2010-06-02, Last modification date: 2024-10-30)
Primary citationFreeman-Cook, K.D.,Autry, C.,Borzillo, G.,Gordon, D.,Barbacci-Tobin, E.,Bernardo, V.,Briere, D.,Clark, T.,Corbett, M.,Jakubczak, J.,Kakar, S.,Knauth, E.,Lippa, B.,Luzzio, M.J.,Mansour, M.,Martinelli, G.,Marx, M.,Nelson, K.,Pandit, J.,Rajamohan, F.,Robinson, S.,Subramanyam, C.,Wei, L.,Wythes, M.,Morris, J.
Design of selective, ATP-competitive inhibitors of Akt.
J.Med.Chem., 53:4615-4622, 2010
Cited by
PubMed Abstract: This paper describes the design and synthesis of novel, ATP-competitive Akt inhibitors from an elaborated 3-aminopyrrolidine scaffold. Key findings include the discovery of an initial lead that was modestly selective and medicinal chemistry optimization of that lead to provide more selective analogues. Analysis of the data suggested that highly lipophilic analogues would likely suffer from poor overall properties. Central to the discussion is the concept of optimization of lipophilic efficiency and the ability to balance overall druglike propeties with the careful control of lipophilicity in the lead series. Discovery of the nonracemic amide series and subsequent modification produced an advanced analogue that performed well in advanced preclinical assays, including xenograft tumor growth inhibition studies, and this analogue was nominated for clinical development.
PubMed: 20481595
DOI: 10.1021/jm1003842
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.49 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon